AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$7.69
−$0.21 (−2.66%) 4:00 PM ET
After hours$7.70
+$0.01 (+0.13%) 4:33 AM ET
Prev closePrevC$7.90
OpenOpen$7.98
Day highHigh$8.03
Day lowLow$7.65
VolumeVol1,382,768
Avg volAvgVol1,699,045
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$415.02M
P/E ratio
0.72
FY Revenue
$2.80M
EPS
10.69
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
UPB
Upstream Bio, Inc.
Upstream Bio, Inc. demonstrates strong technical momentum with multiple bullish breakouts and confirmed volume participation, while its fundamental profile is characterized by significant losses and negative profitability metrics. Analyst sentiment is decisively positive with high upside targets, but valuation and short interest metrics highlight elevated risk and speculative positioning.
AI summarized at 2:24 PM ET, 2025-09-03
Volume vs average
Intraday (cumulative)
−48% (Below avg)
Vol/Avg: 0.52×
RSI
18.65(Oversold)
Oversold (<30)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.00 Signal: -0.00
Short-Term
-0.86 (Weak)
MACD: -5.87 Signal: -5.01
Long-Term
-1.53 (Weak)
MACD: -6.52 Signal: -4.99
Intraday trend score
39.00
LOW39.00HIGH54.00
Latest news
UPB•7 articles•Positive: 6Neutral: 1Negative: 0
PositiveGlobeNewswire Inc.• Upstream Bio, Inc.
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
Upstream Bio announced additional analyses from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP). The drug met its primary endpoint with a nasal polyp score reduction of -1.95 (p < 0.0001) and reduced the need for surgery or systemic corticosteroids by 76% compared to placebo. The company plans to initiate Phase 3 trials in CRSwNP and severe asthma following regulatory interactions.
The company reported positive Phase 2 trial results with statistically significant improvements in primary and secondary endpoints. The drug demonstrated strong efficacy with reduced need for rescue interventions and a favorable safety profile. Plans to advance to Phase 3 trials in multiple indications indicate confidence in the drug's potential and represent significant clinical progress.
PositiveGlobeNewswire Inc.• Upstream Bio, Inc.
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
Upstream Bio announced it will present additional efficacy analyses from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps at the AAAAI Congress 2026. The presentation will include new analyses assessing verekitug's efficacy with adjustment for concomitant rescue therapy use. Verekitug is a novel monoclonal antibody targeting the TSLP receptor and is currently in development for multiple inflammatory diseases including severe asthma and COPD.
The company is presenting additional positive data from its Phase 2 VIBRANT trial, demonstrating continued progress in clinical development of verekitug. The announcement of multiple ongoing Phase 2 trials across different indications (CRSwNP, severe asthma, COPD) and the initiation of a long-term extension study (VALOUR trial) indicate advancement in the pipeline and positive momentum in the development program.
NeutralGlobeNewswire Inc.• Not Specified
Upstream Bio to Participate in Upcoming March Investor Conferences
Upstream Bio announced that CEO Rand Sutherland will participate in two major investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference on March 4 and the Leerink Partners Global Healthcare Conference on March 9. The company is developing verekitug, a TSLP receptor antagonist in Phase 2 trials for severe respiratory disorders including chronic rhinosinusitis with nasal polyps, severe asthma, and COPD.
The article is primarily an announcement of conference participation with no new clinical data or material developments disclosed. While the company mentions positive Phase 2 VALIANT trial results in the header, the main article content focuses only on the upcoming investor conference schedule, which is routine corporate communication without significant positive or negative implications.
PositiveGlobeNewswire Inc.• Na
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
Upstream Bio announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, a TSLP receptor antagonist for severe asthma treatment, on February 11, 2026. The trial evaluated 478 patients across multiple dosing regimens in a randomized, double-blind, placebo-controlled study.
The company is advancing a novel therapeutic candidate (verekitug) through Phase 2 clinical trials with positive momentum. The announcement of top-line results from a well-designed 478-patient trial demonstrates progress in drug development. The company is also expanding into multiple indications (asthma, CRSwNP, COPD), indicating confidence in the drug's potential and addressing significant unmet medical needs.
PositiveGlobeNewswire Inc.• Meggan Buckwell
Upstream Bio to Participate in Upcoming November Investor Conferences
Upstream Bio, a clinical-stage biotechnology company, will participate in multiple investor conferences in November 2025, presenting its research on verekitug, a potential treatment for inflammatory respiratory diseases.
Company is actively presenting at multiple investor conferences, showcasing ongoing clinical development of a novel therapeutic approach for inflammatory respiratory diseases
PositiveGlobeNewswire Inc.• Upstream Bio, Inc.
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
Upstream Bio presented data at the EAACI Congress showing that its novel antibody verekitug, which targets the TSLP receptor, has greater potency compared to treatments targeting the TSLP ligand. This suggests verekitug may have a differentiated profile across inflammatory diseases like severe asthma, COPD, and chronic rhinosinusitis.
The article presents positive data on Upstream Bio's novel antibody verekitug, which suggests it may have a differentiated profile and greater potency compared to other treatments targeting the TSLP pathway. This could translate to clinical benefits for patients with severe respiratory diseases.
PositiveGlobeNewswire Inc.• N/A
Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
Upstream Bio, a clinical-stage company, will present data at the EAACI Congress 2025 that supports the use of its novel antibody, verekitug, in targeting the TSLP receptor for greater potency in treating inflammatory diseases.
UPBUpstream BioverekitugTSLP receptorEAACI Congress 2025
Sentiment note
The article highlights Upstream Bio's progress in developing verekitug, a novel antibody targeting the TSLP receptor, and its upcoming presentation at a major medical conference, which suggests the company is making advancements in its pipeline.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
